Related Experiment Video
Updated: May 10, 2026
14:57
Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
Compensating for synaptic loss in Alzheimer's disease.
Kamal Abuhassan1, Damien Coyle, Ammar Belatreche
1Intelligent Systems Research Centre, University of Ulster, Magee Campus, Derry, BT48 7JL, UK, Abuhassan-k@email.ulster.ac.uk.
Journal of Computational Neuroscience
|June 4, 2013
Summary
Synaptic loss in Alzheimer's disease (AD) impacts cognition. This study models how local compensation preserves theta/alpha brain waves, while global compensation supports delta/beta waves, suggesting targeted therapies.
Area of Science:
- Neuroscience
- Computational Biology
- Systems Neuroscience
Background:
- Synaptic loss is a hallmark of Alzheimer's disease (AD), correlating with cognitive decline.
- Compensation mechanisms in neural circuits attempt to mitigate synaptic loss and maintain cognitive function.
- Understanding the interplay between synaptic degeneration, compensation, and brain oscillations is crucial for AD research.
Purpose of the Study:
- To investigate the relationship between synaptic degeneration, compensation mechanisms, and abnormal cortical oscillations in Alzheimer's disease.
- To model the effects of local and global compensation strategies on different brain wave frequencies.
- To explore the potential of targeted compensation enhancement for cognitive recovery in AD.
Main Methods:
- Utilized a large-scale computational network model (100,000 neurons, 8.5 million synapses) with realistic features like short-term plasticity and axonal delays.
- Simulated various synaptic degeneration and compensation scenarios within the cortical network model.
- Analyzed the impact of distinct compensation mechanisms on theta, alpha, delta, and beta oscillations.
Main Results:
- Cortical oscillations exhibit differential responses to local and global compensation mechanisms.
- Local compensation primarily preserves theta (5-7 Hz) and alpha (8-12 Hz) oscillations.
- Global compensation is more effective in maintaining delta (1-4 Hz) and beta (13-30 Hz) oscillations.
- Independent application of compensation mechanisms yielded greater benefits than combined, parallel application.
- Inappropriate compensation strategies may lead to network dysfunction or secondary pathological changes.
Conclusions:
- Targeting local compensation may restore cognitive functions linked to theta and alpha oscillations.
- Inducing global compensation could aid in repairing neural processes associated with delta and beta band activity.
- Compensation mechanisms are region-specific, and misapplication can be detrimental.
- This modeling study provides insights into potential therapeutic strategies for Alzheimer's disease by modulating brain oscillations through targeted compensation.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:03Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
01:05Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...